What is the latest BAFNAPH stock price?
The latest stored price for BAFNAPH is Rs 233.58 as of 2026-07-21.
gimli
BAFNAPH stock AI analysis
BAFNAPH Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
BAFNA PHARMACEUTICALS LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available BAFNAPH price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹233.58
1W return
+9.73%
1M return
+45.81%
3M return
+71.18%
6M return
+108.42%
1Y return
+161.68%
Market cap
₹552.56 cr
PE
49.78
PB
5.75
ROE
+12.27%
ROCE
+11.87%
RSI
73.30
Turnover
₹0.09 cr
Why it can matter in screens
- Momentum: BAFNAPH is above 50DMA, above 200DMA; RSI is 73.30.
- Returns: 1D +2.00%, 1W +9.73%, 1M +45.81%, 3M +71.18%, 1Y +161.68%.
- Trend levels: 52W high ₹233.58, 52W low ₹81.38, off high +0.00%.
- Liquidity: latest turnover is ₹0.09 cr; volume vs 20D is +0.41%.
- Valuation/profitability: PE 49.78, PB 5.75, ROE +12.27%, ROCE +11.87%.
- Growth: 3Y sales CAGR +9.30%, 3Y profit CAGR -0.71%.
Quick Answers
Is BAFNAPH above its 50DMA and 200DMA?
BAFNAPH is above 50DMA, above 200DMA. The latest 50DMA is 173.90 and the latest 200DMA is 146.77.
What are BAFNAPH PE, ROE and ROCE?
BAFNAPH has PE 49.78, ROE +12.27%, and ROCE +11.87% in Gimli's latest available snapshot.
How has BAFNAPH performed recently?
BAFNAPH has returned +45.81% over 1 month, +71.18% over 3 months, and +161.68% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 42.24 cr | 5.31 cr | 2.75 cr | 1.16 |
| 2025-12-31 | 38.29 cr | 4.27 cr | 1.84 cr | 0.78 |
| 2025-09-30 | 35.47 cr | 5.46 cr | 3.12 cr | 1.32 |
| 2025-06-30 | 34.62 cr | 5.66 cr | 3.39 cr | 1.43 |
| 2025-03-31 | 39.06 cr | 2.35 cr | 1.31 cr | 0.55 |
| 2024-12-31 | 33.19 cr | 3.24 cr | n/a | nan |
| 2024-09-30 | n/a | n/a | n/a | 1.11 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 150.62 cr | 20.70 cr | 11.10 cr | 4.69 |
| 2025-03-31 | 145.86 cr | 11.77 cr | 4.15 cr | 1.76 |
| 2024-03-31 | 152.47 cr | 14.28 cr | 7.35 cr | 3.11 |
| 2023-03-31 | 115.35 cr | 18.75 cr | 11.34 cr | 4.79 |
| 2022-03-31 | n/a | n/a | n/a | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 175.53 cr | 2.02 cr | 37.43 cr | 96.15 cr |
| 2025-03-31 | 153.08 cr | 3.43 cr | 28.20 cr | 84.81 cr |
| 2024-03-31 | 147.68 cr | 1.40 cr | 24.39 cr | 80.84 cr |
| 2023-03-31 | 129.58 cr | 7.81 cr | 22.92 cr | 73.45 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 15.37 cr | -9.53 cr | n/a |
| 2025-03-31 | 22.14 cr | 0.28 cr | n/a |
| 2024-03-31 | 9.48 cr | -6.36 cr | n/a |
| 2023-03-31 | 4.95 cr | -3.27 cr | n/a |
| 2022-03-31 | n/a | n/a | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +75.00% | +9.34% | +0.00% | +0.00% | +15.66% | +0.00% |
| 2025-12-31 | +75.00% | +9.34% | +0.00% | +0.00% | +15.66% | +0.00% |
| 2025-09-30 | +75.00% | +9.34% | +0.00% | +0.00% | +15.66% | +0.00% |
| 2025-06-30 | +75.00% | +9.34% | +0.00% | +0.00% | +15.66% | +0.00% |
| 2025-03-31 | +75.00% | +8.53% | +0.00% | +0.00% | +16.47% | +0.00% |
| 2024-12-31 | +88.30% | +0.00% | +0.00% | +0.00% | +11.70% | +0.00% |
| 2024-09-30 | +88.30% | +0.00% | +0.00% | +0.00% | +11.70% | +0.00% |
| 2024-06-30 | +88.30% | +0.00% | +0.00% | +0.00% | +11.70% | +0.00% |
| 2024-03-31 | +88.30% | +0.00% | +0.00% | +0.00% | +11.70% | +0.00% |
| 2023-12-31 | +88.43% | +0.00% | +0.00% | +0.00% | +11.57% | n/a |
| 2023-09-30 | +88.74% | +0.00% | +0.00% | +0.00% | +11.26% | n/a |
| 2023-06-30 | +90.00% | +0.00% | +0.00% | +0.00% | +10.00% | n/a |
| 2023-03-31 | +90.00% | +0.00% | +0.00% | +0.00% | +10.00% | n/a |
| 2022-12-31 | +90.02% | +0.00% | +0.00% | +0.00% | +9.98% | n/a |
| 2022-09-30 | +90.00% | +0.00% | +0.00% | +0.00% | +10.00% | n/a |
| 2022-06-30 | +90.12% | +0.00% | +0.00% | n/a | n/a | +0.00% |
| 2022-03-31 | +90.42% | +0.00% | +0.00% | n/a | n/a | n/a |
| 2021-12-31 | +90.42% | +0.00% | +0.00% | n/a | n/a | +0.00% |
| 2021-09-30 | +90.40% | +0.00% | +0.00% | n/a | n/a | +0.00% |
| 2021-06-30 | +90.39% | +0.00% | +0.00% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 470,725.53 cr | 40.938102 | +14.71% | +15.93% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,588.48 cr | 75.774332 | +16.19% | +9.60% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 170,600.17 cr | 78.872017 | +17.18% | +43.04% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,349.41 cr | 65.537894 | +21.03% | +23.05% |
| CIPLA | CIPLA LTD | 115,717.42 cr | 29.815932 | +11.79% | -2.81% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,022.61 cr | 22.938459 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 114,980.65 cr | 21.532280 | +26.83% | +30.91% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,095.75 cr | 74.247785 | +14.33% | -9.67% |
Try these prompts
- Analyze BAFNA PHARMACEUTICALS with valuation, momentum and industry peers
- Compare BAFNAPH with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare BAFNAPH with other Healthcare stocks
Data snapshot: 2026-07-21. Not investment advice.